MedTrace Logo

Contrast-Induced Acute Kidney Injury Prevention in Acute Heart Failure

NCT07550790 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2026-07-16

No results posted yet for this study

Summary

The K-PROSE study is a randomized clinical investigation evaluating strategies to prevent contrast-induced acute kidney injury (CI-AKI) in patients hospitalized with acute heart failure and moderate renal dysfunction (eGFR 30-75 mL/min/1.73 m²). Patients requiring contrast-enhanced CT imaging are randomized to either standard intravenous saline hydration or a furosemide-based decongestion strategy. Renal function is assessed using serial measurements of creatinine and cystatin C, before and after contrast exposure. By comparing renal outcomes, congestion status, and safety profiles, this study aims to determine whether a decongestion-focused approach provides superior renal protection compared with conventional hydration in high-risk acute heart failure patients.

Conditions

  • Heart Failure Acute
  • Renal Dysfunction

Interventions

DRUG

Furosemide

Intravenous furosemide administered to promote diuresis as part of a decongestion-based renal protection strategy.

DRUG

0.9 % Normal Saline

Intravenous isotonic saline administered as standard hydration for the prevention of contrast-induced acute kidney injury.

Sponsors & Collaborators

  • Jin Joo Park

    lead OTHER

Principal Investigators

  • Jin Joo Park, MD, PhD · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07550790 on ClinicalTrials.gov